Fatty liver treating Chinese medicine and method for preparing the same

Abstract

The present invention provides a Chinese traditional patent medicine to treat primary and secondary fatty liver, which is prepared by the pharmaceutical raw materials with the following parts by weight: 9 to 15 parts of cassia seed, 9 to 15 parts of hawthorn and 3 to 9 parts of American ginseng. The preparation method of the product of the present invention is that: all the pharmaceutical raw materials with the mix ratio by weight are extracted by 30 to 90 percent ethanol refluxing, and the acceptable excipients on pharmacy are added into the extraction liquid to prepare the commonly used formulation on pharmacy. The present invention clinically provides a Chinese traditional patent medicine to treat fatty liver and has the definite efficacy, less toxicity and side effects, controllable manufacturing quality and low cost, thus the invention can make up a plurality of disadvantages of the drugs for treating fatty liver in the prior art.

Description

technical field [0001] The invention relates to a Chinese patent medicine for treating primary and secondary fatty liver and a preparation method thereof. Background technique [0002] Fatty liver is hepatic steatosis caused by a variety of diseases and etiologies. The accumulation of lipid in liver cells exceeds 5% of the wet weight of the liver or histologically sees 1 / 3 of the hepatocytes per unit area. It is called fatty liver . According to statistics, there are about 140 million fatty liver patients in my country. In large and medium-sized cities in China, the incidence of fatty liver has reached 8-10% of the total population, the incidence of Shanghai has reached 30% of the total population, and the incidence of Beijing has reached 26.1% of the total population. %. In white-collar workers, the incidence rate of fatty liver is as high as 25%; the incidence rate of obese patients and type II diabetes patients is as high as 50%. Fatty liver mostly occurs in young and m...

AI Technical Summary

Problems solved by technology

[0003] The current drugs for the treatment of fatty liver have the following problems: ①The curative effect is not exact and the effect is unreliable

The adverse reactions of the new generation of nicotinic acid drugs are significantly less than before, but their efficacy is far inferior to that of clofibrate; antioxidants may reduce oxygen stress damage to liver fibrosis caused by lipid peroxidation, but their exact efficacy has yet to be proven; Rebound of transaminases often occurs after withdrawal of hepatoprotective and enzyme-lowering drugs

② Toxic and side effects

For example, the adverse reactions of clofibrate esters are mainly manifested as epigastric discomfort, burning sensation of fullness, loss of appetite, and mild diarrhea; long-term use of choline and methionine has the risk of inducing hepatic encephalopathy; metformin has potential hepatic encephalopathy. Toxicity issues; although lipid-lowering drugs are widely used in the treatment of fatty liver, there is controversy: many blood lipid-lowering drugs may promote blood lipids to be more concentrated in the liver for metabolism, and also promote lipid accumulation and damage liver function, so in the absence of Patients with obvious hyperlipidemia should not blindly take lipid-lowering drugs for a long time

③ Expensive

S-adenosylmethionine such as "Simite" is effective in treating alcoholic fatty liver and cholestatic liver disease, but it is expensive and difficult to be widely used clinically in the near future; another example is Panax notoginseng Fatty liver pills are water honey pills made from dozens of herbs such as Panax notoginseng and curcuma. The dosage form is backward, the dosage is large, and the price is expensive.

Images